1.. Introduction
================

Poly(ADP-ribose) polymerases (PARPs) are a large protein family involved in various cellular and molecular processes ([@b1-ol-0-0-9551]--[@b8-ol-0-0-9551]). PARPs transfer ADP-ribose molecules from donor NAD^+^ to target proteins by post-translational modification, including poly(ADP-ribosyl)ation (PARsylation) ([@b1-ol-0-0-9551]--[@b3-ol-0-0-9551]). PARsylation regulates numerous cellular processes, including DNA damage repair ([@b4-ol-0-0-9551]), cellular stress signaling ([@b5-ol-0-0-9551]), gene transcription ([@b6-ol-0-0-9551],[@b7-ol-0-0-9551]) and ageing ([@b8-ol-0-0-9551]). There are 17 physiological human PARPs ([@b9-ol-0-0-9551]).

The two tankyrase proteins, tankyrase 1 (TNKS1; also known as PARP5A and ARTD5) and tankyrase 2 (TANK2; also known as PARP5B and ARTD6), belong to the PARP family ([@b3-ol-0-0-9551]). TNKS1 consists of an amino-terminal domain composed of homopolymeric stretches of His, Pro and Ser residues (the HPS domain), an ankyrin domain composed of 24 ankyrin repeats, a sterile α module (SAM) domain and a carboxy-terminal PARP catalytic domain ([@b10-ol-0-0-9551],[@b11-ol-0-0-9551]). TANK2 is associated with TNKS1 ([@b10-ol-0-0-9551]), but lacks an N-terminal HPS domain. The TANK2 ANK domain shares 83% identity with TNKS1, and the TANK2 SAM domain shares 74% identity with that of TNKS1 ([@b10-ol-0-0-9551]). The C-terminal PARP domain is a PARP polymerase and is highly conserved, with 94% identity ([@b10-ol-0-0-9551]). The ankyrin domain is implicated in protein-protein interactions ([@b12-ol-0-0-9551]), and the SAM domain is implicated in self-oligomerization ([@b13-ol-0-0-9551]). The HPS domain function is currently unknown.

Tankyrases interact with a number of target proteins and regulate cellular processes, including telomere maintenance, via telomere repeat binding factor 1 (TRF1) ([@b10-ol-0-0-9551]). Tankyrase-binding partners interact with TNKS1 using a 6-amino acid tankyrase-binding motif (RxxAxG, RxxPxG or RxxxxG) ([@b14-ol-0-0-9551]--[@b17-ol-0-0-9551]).

Tankyrases are involved in various cellular functions, including telomere maintenance ([@b18-ol-0-0-9551]), Wnt signaling ([@b15-ol-0-0-9551]), mitosis ([@b19-ol-0-0-9551]--[@b22-ol-0-0-9551]), glucose metabolism ([@b23-ol-0-0-9551],[@b24-ol-0-0-9551]) and heritable disease cherubism ([@b14-ol-0-0-9551],[@b25-ol-0-0-9551]). Recent studies reported novel tankyrase binding partners, including phosphatase and tensin homolog (PTEN), peroxiredoxin II (PrxII), adenomatous polyposis coli 2 (APC2), angiomotins (AMOTs), abraxas brother 1 (ABRO1), cluster of differentiation 2 associated protein (CD2AP), peroxisomal biogenesis factor 14 (PEX14) and autophagy related 9A (ATG9A), as detailed in [Table I](#tI-ol-0-0-9551){ref-type="table"} ([@b16-ol-0-0-9551],[@b26-ol-0-0-9551]--[@b31-ol-0-0-9551]). These data indicate novel tankyrase functionalities and provide novel insights for further investigations in numerous cellular responses. The present review focuses on novel tankyrase-binding partners and discusses recent data on tankyrase roles in cancer.

2.. Post-translational modification and tankyrase activity
==========================================================

### PARsylation and ubiquitination

Tankyrases catalyze post-translational modification of target proteins, which controls their stability ([@b15-ol-0-0-9551],[@b32-ol-0-0-9551]). TNKS1 PARsylates tankyrase target proteins, including TRF1, centrosomal P4.1-associated protein (CPAP), AXIN, PTEN and AMOTs ([@b15-ol-0-0-9551],[@b16-ol-0-0-9551],[@b21-ol-0-0-9551],[@b32-ol-0-0-9551],[@b33-ol-0-0-9551]). The PARsylated protein is then recognized by the E3 ligase, and targeted for ubiquitination and proteasomal degradation ([@b15-ol-0-0-9551],[@b16-ol-0-0-9551],[@b26-ol-0-0-9551]).

### Tankyrase activity

Tankyrase activity is controlled by a variety of factors, including polo-like kinase-1 (PLK1) and mitogen-activated protein kinase (MAPK). TNKS1 is phosphorylated by PLK1, glycogen synthase kinase 3 (GSK3), and MAPK, although the precise functions of this modification are not clear ([@b34-ol-0-0-9551]--[@b36-ol-0-0-9551]). PLK1-mediated phosphorylation results in increased TNKS1 stability and telomeric PARP activity ([@b34-ol-0-0-9551]). GSK3-mediated phosphorylation of TNKS1 does not alter TNKS1 auto-PARsylation *in vitro*, and MAPK-mediated phosphorylation of tankyrase enhances the PARsylation activity of TNKS1 *in vitro* ([@b35-ol-0-0-9551],[@b36-ol-0-0-9551]). GDP-mannose 4, 6-dehydratase binds to TNKS1, inhibits tankyrase PARP activity *in vitro* and influences TNKS1 stability *in vivo* ([@b37-ol-0-0-9551]). Kang *et al* ([@b26-ol-0-0-9551]) demonstrated that TNKS1 is involved with the antioxidant enzyme PrxII. PrxII is essential for full TNKS1 activity, in order to maintain oncogenic β-catenin signaling in colorectal cancer (CRC). This study demonstrated the molecular mechanisms regulating tankyrase activity in CRC for the first time.

3.. Tankyrase and cancer
========================

Different biological tankyrase functions are relevant to cancer, including telomere maintenance, oncogenic pathways \[Wnt, yes-associated protein (YAP) and AKT\], mitosis, DNA repair and cell death, as depicted in [Fig. 1](#f1-ol-0-0-9551){ref-type="fig"}.

### Telomere maintenance

TNKS1 has been identified as an interaction partner of TRF1 ([@b18-ol-0-0-9551],[@b38-ol-0-0-9551]). TRF1 blocks the access of telomerase to telomeres ([@b18-ol-0-0-9551],[@b32-ol-0-0-9551]). TNKS1-mediated PARsylation of TRF1 releases TRF1 from telomeres, and the released TRF1 is degraded by the ubiquitin-proteasome pathway ([@b18-ol-0-0-9551],[@b32-ol-0-0-9551]). Telomere maintenance by telomerase allows continued proliferation of cancer cells and is considered as a promising target for anticancer strategies. TNKS1 controls telomerase inhibition in human cancer cells and is a potential telomere-directed anticancer target ([@b39-ol-0-0-9551],[@b40-ol-0-0-9551]). Telomere-directed inhibitors result in progressive telomere shortening, with no acute cytotoxicity, and combination with tankyrase inhibitors has been proposed ([@b39-ol-0-0-9551],[@b40-ol-0-0-9551]). Dual inhibition of TNKS1 and telomerase has demonstrated a synergistic effect in lung and gastric cancer cell lines ([@b41-ol-0-0-9551],[@b42-ol-0-0-9551]). Furthermore, the combination of tankyrase and telomerase inhibition promotes human lung adenocarcinoma cell apoptosis and inhibits proliferation ([@b41-ol-0-0-9551]). These observations indicate that co-inhibition of telomerase and tankyrase may be an effective strategy for the treatment of lung cancer in humans.

### Oncogenic pathways

Tankyrases have been implicated in oncogenic pathways (Wnt, YAP and AKT) ([@b15-ol-0-0-9551],[@b16-ol-0-0-9551],[@b43-ol-0-0-9551]).

### Wnt signaling

The Wnt signal transduction pathway regulates numerous biological processes in diseases such as in cancer ([@b44-ol-0-0-9551]). AXIN is the key effector in the Wnt pathway and has been identified as a tumor suppressor. Tankyrases target AXIN for degradation, whereas tankyrase inhibitors generally stabilize it ([@b44-ol-0-0-9551],[@b45-ol-0-0-9551]). The Wnt pathway regulates proteolysis of the downstream effector β-catenin with the β-catenin destruction complex, which includes adenomatous polyposis coli (APC), AXIN and GSK3β ([@b45-ol-0-0-9551]). TNKS1-mediated AXIN PARsylation induces AXIN degradation with the ubiquitin-proteasome pathway, and the ensuing AXIN degradation triggers disruption of the β-catenin destruction complex ([@b15-ol-0-0-9551]). Released β-catenin translocates into the nucleus and switches on Wnt-dependent transcription ([@b44-ol-0-0-9551]).

The tumor suppressor APC scaffolds the β-catenin destruction complex ([@b45-ol-0-0-9551]). APC is mutated in \>80% of CRC cases ([@b46-ol-0-0-9551]). Therefore, due to tankyrases regulating Wnt signaling, tankyrase inhibitors may be promising therapeutic targets for CRC. TNKS1 inhibition suppresses Wnt signaling and tumor growth in APC-mutant colorectal tumors ([@b15-ol-0-0-9551],[@b47-ol-0-0-9551],[@b48-ol-0-0-9551]), and increases chemosensitivity in colon cancer cell lines ([@b49-ol-0-0-9551]). Due to the Wnt pathway being involved in lung cancer ([@b50-ol-0-0-9551],[@b51-ol-0-0-9551]), antagonizing the Wnt pathway through tankyrase inhibition may be effective against lung cancer, and there is evidence for tankyrases as antineoplastic targets in lung cancer ([@b52-ol-0-0-9551],[@b53-ol-0-0-9551]).

Croy *et al* ([@b27-ol-0-0-9551]) indicated that the fly APC homolog APC2 may be a tankyrase substrate and that tankyrases regulate destruction complex activity, providing additional insight into tankyrase inhibition as a potential Wnt-pathway cancer therapy.

### YAP signaling

The Hippo pathway controls tissue homeostasis and organ size ([@b54-ol-0-0-9551],[@b55-ol-0-0-9551]). YAP has been identified as an oncoprotein and the key effector in the Hippo pathway ([@b54-ol-0-0-9551]--[@b58-ol-0-0-9551]). YAP signaling has also been demonstrated to be involved in human cancer types ([@b56-ol-0-0-9551]--[@b58-ol-0-0-9551]). AMOTs are negative YAP regulators ([@b33-ol-0-0-9551]), and recent studies indicated that tankyrase inhibition suppresses YAP oncogenic activity by stabilizing AMOTs through inhibiting their tankyrase RNF146 axis-mediated degradation ([@b28-ol-0-0-9551],[@b59-ol-0-0-9551]). These results indicate a potential opportunity for cancer therapy. Lin *et al* ([@b43-ol-0-0-9551]) demonstrated that YAP signaling is involved in drug resistance, including with RAF- and MAPK-targeted cancer therapy. Wang *et al* ([@b59-ol-0-0-9551]) reported that tankyrase inhibition enhances epidermal growth factor receptor (EGFR) growth inhibition in non-small cell lung cancer (NSCLC). These data indicate that tankyrase inhibition could be an effective approach to overcome drug resistance for combinatorial cancer therapy.

### AKT signaling

PTEN is an important tumor suppressor, and PTEN mutations have been associated with a number of cancer types ([@b60-ol-0-0-9551],[@b61-ol-0-0-9551]) and Cowden syndrome ([@b62-ol-0-0-9551]). Li *et al* ([@b16-ol-0-0-9551]) identified PTEN as a tankyrase-binding protein. PTEN stabilization by tankyrase inhibition induces downregulation of AKT phosphorylation, suppressing cell proliferation and tumor growth. These data support the therapeutic potential of tankyrase inhibitors targeting the AKT oncogenic pathway.

### Mitosis regulation

TNKS1 is required to resolve sister telomeres during mitosis. Sister chromatid cohesion holds sister chromatids together from their S phase replication until their mitosis separation ([@b22-ol-0-0-9551],[@b29-ol-0-0-9551]). Cohesion requires a multi-protein complex comprising structural maintenance of chromosomes protein (Smc)1, Smc3, sister chromatid cohesion protein (Scc)1 and Scc3 ([@b63-ol-0-0-9551],[@b64-ol-0-0-9551]). In the absence of TNKS1, cohesion is removed from arms and centromeres, but sister telomeres remain associated, indicating persistent cohesion, and this persistent telomere cohesion by TNKS1 inhibition during mitosis induces a delay in anaphase progression ([@b22-ol-0-0-9551]). Tripathi and Smith ([@b29-ol-0-0-9551]) demonstrated that the mechanism of cell cycle-regulated K63-ubiquitination of tankyrase controls sister telomere resolution timing.

TNKS1 colocalizes with the nuclear mitotic apparatus (NuMA) protein and PARsylates NuMA in mitosis ([@b20-ol-0-0-9551]), and TNKS1-depleted cells exhibit defects in mitotic spindle assembly and structure ([@b19-ol-0-0-9551]), indicating that TNKS1 is required for normal spindle formation. TNKS1 also localizes at the centrosomes, promotes centrosome maturation, interacts with CPAP, PARsylates CPAP, and regulates CPAP protein stability and function at centrosomes across the cell cycle ([@b21-ol-0-0-9551]). Miki PARsylation by TNKS1 promotes centrosome maturation ([@b65-ol-0-0-9551]); therefore, CPAP and Miki may have a general role in centrosome function. Abnormal centrosomes are involved in cancer and contribute to chromosome missegregation and aneuploidy, thereby promoting malignant progression ([@b66-ol-0-0-9551]--[@b69-ol-0-0-9551]). Korzeniewski *et al* ([@b70-ol-0-0-9551]) indicated centrosomes as a potential target for cancer therapy.

### DNA repair

The DNA-dependent protein kinase (DNA-PK) is a critical component of non-homologous end joining-mediated DNA repair mechanisms ([@b71-ol-0-0-9551]). DNA-PKcs, a catalytic subunit of DNA-PK, exists in a PARsylated state *in vitro* and *in vivo* ([@b72-ol-0-0-9551],[@b73-ol-0-0-9551]). TNKS1 regulates DNA repair via PARsylation-mediated stabilization of DNA-PK and suppression of telomere-associated sister chromatid exchange ([@b74-ol-0-0-9551]). Tankyrases bind to mediator of DNA damage checkpoint protein 1 and promote homologous recombination and checkpoint activation in response to double-strand breaks (DSBs) ([@b75-ol-0-0-9551]). Therefore, tankyrases have a direct role in DSB repair. DNA-PK is involved in tumor-associated processes, including genomic stability, hypoxia, metabolism, inflammatory response and transcription ([@b71-ol-0-0-9551]), which indicates that DNA-PK may be a potential target for cancer therapy.

### Cell death

Tankyrase inhibition blocks proliferation and promotes cell apoptosis in neuroblastoma (NB) cell lines; therefore, tankyrases are a potential target for NB ([@b17-ol-0-0-9551]).

4.. Tankyrase inhibitors
========================

Numerous studies have reported the importance and utility of tankyrase inhibitors as cancer therapeutics ([@b15-ol-0-0-9551],[@b47-ol-0-0-9551],[@b48-ol-0-0-9551],[@b52-ol-0-0-9551],[@b76-ol-0-0-9551]--[@b80-ol-0-0-9551]). Consequently, a number of tankyrase inhibitors with promising therapeutic effects have been developed, including XAV939, IWR-1, G007-LK, JW55, AZ1366, JW 74 and NVP-TNKS656 ([@b15-ol-0-0-9551],[@b47-ol-0-0-9551],[@b48-ol-0-0-9551],[@b52-ol-0-0-9551],[@b76-ol-0-0-9551]--[@b80-ol-0-0-9551]) ([Table II](#tII-ol-0-0-9551){ref-type="table"}).

Tankyrase inhibition suppresses Wnt signaling and tumor growth in APC-mutant colorectal tumors ([@b15-ol-0-0-9551],[@b47-ol-0-0-9551],[@b48-ol-0-0-9551]). Wu *et al* ([@b49-ol-0-0-9551]) demonstrated that the tankyrase inhibitor XAV939 increased chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway. Lau *et al* ([@b47-ol-0-0-9551]) indicated that the tankyrase inhibitor G007-LK suppressed APC-mutant colorectal tumor growth. Mashima *et al* ([@b81-ol-0-0-9551]) reported that mechanistic target of rapamycin (mTOR) signaling conferred resistance to tankyrase inhibitors in Wnt-driven CRC, indicating that co-inhibition of tankyrase and mTOR may be an effective therapeutic approach for CRC.

The Wnt pathway is also involved in lung cancer ([@b50-ol-0-0-9551],[@b51-ol-0-0-9551]), and therefore antagonizing the Wnt pathway through tankyrase inhibition could be effective against lung cancer. Casás-Selves *et al* ([@b53-ol-0-0-9551]) and Busch *et al* ([@b52-ol-0-0-9551]) demonstrated tankyrase to be an antineoplastic target in lung cancer. Wang *et al* ([@b59-ol-0-0-9551]) indicated that the tankyrase inhibitor NVP-TNKS656 sensitized lung cancer cells to the EGFR inhibitor erlotinib. Busch *et al* ([@b52-ol-0-0-9551]) screened A375 melanoma cells and identified WIKI4, a small molecule inhibitor of Wnt/β-catenin signaling.

Co-localization of the transcription factor forkhead box O3 and β-catenin in the nucleus mediates progression and metastasis in CRC upon phosphoinositide 3-kinase (PI3K) or AKT inhibition ([@b36-ol-0-0-9551],[@b82-ol-0-0-9551]). Co-exposure to AKT or PI3K inhibitors and the tankyrase inhibitor XAV939 impairs metastasis. Arqués *et al* ([@b76-ol-0-0-9551]) demonstrated that the tankyrase inhibitor NVP-TNKS656 blocked the Wnt/β-catenin pathway, overcoming resistance to PI3K and AKT inhibitors in CRC.

Thomson *et al* ([@b83-ol-0-0-9551]) characterized a novel tankyrase inhibitor, tetrazoloquinoxaline 41, and indicated that it inhibited growth in tumor-derived cell lines, providing a potential cancer therapy.

5.. Novel tankyrase binding partners
====================================

Numerous tankyrase binding partners have been reviewed ([@b2-ol-0-0-9551]), and a number of studies have recently reported novel tankyrase binding partners ([@b16-ol-0-0-9551],[@b26-ol-0-0-9551]--[@b31-ol-0-0-9551]). This section reviews a number of these novel tankyrase binding partners, including PTEN, PrxII, APC2, AMOTs, ABRO1, CD2AP, PEX14 and ATG9A ([Table I](#tI-ol-0-0-9551){ref-type="table"}).

### PTEN

PTEN has been characterized as a tumour suppressor, and PTEN mutations have been reported in cancers ([@b60-ol-0-0-9551],[@b61-ol-0-0-9551]) and Cowden syndrome ([@b62-ol-0-0-9551]). Li *et al* ([@b16-ol-0-0-9551]) identified PTEN as a tankyrase-binding protein containing a RXXXDG tankyrase-binding motif (RYQEDG). Tankyrases interact with and PARsylate PTEN. PARsylated PTEN promotes PTEN degradation through E3 ligase RNF146 ([@b16-ol-0-0-9551]).

PTEN stabilization by tankyrase inhibition induces downregulation of AKT phosphorylation, suppressing cell proliferation and tumor growth ([@b16-ol-0-0-9551]). These data indicate a therapeutic potential for tankyrase inhibitors in cancer, targeting the AKT oncogenic pathway.

### PrxII

Kang *et al* ([@b26-ol-0-0-9551]) demonstrated that TNKS1 is involved with PrxII, and PrxII is essential for full TNKS1 activity to maintain oncogenic β-catenin signaling in CRC. In addition, it was indicated that the TNKS1 zinc-binding motif is essential for PARP activity and is protected from oxidative inactivation by PrxII. Furthermore, H~2~O~2~-dependent inactivation of TNKS1 PARP activity in the absence of PrxII enhances AXIN-dependent β-catenin degradation in APC-mutant CRC cells ([@b26-ol-0-0-9551]). These results indicate that PrxII inhibition may exert therapeutic effects on APC-mutant CRC cells.

### APC2

Of all colon cancer cases, \>80% are initiated by truncating mutations in the tumor suppressor APC ([@b46-ol-0-0-9551]). The Wnt pathway regulates proteolysis of the downstream effector β-catenin via the β-catenin destruction complex, including APC, AXIN and GSK3β ([@b45-ol-0-0-9551]). Croy *et al* ([@b27-ol-0-0-9551]) identified APC2, a fly APC homolog, as a tankyrase binding partner and substrate. This previous study indicated that tankyrases regulate the activity of the β-catenin destruction complex through AXIN and APC2 ribosylation, supporting the therapeutic value of tankyrase inhibition as a Wnt-pathway cancer therapy.

### Angiomotin family of proteins

AMOTs are negative YAP regulators ([@b33-ol-0-0-9551]), and tankyrase inhibition suppresses YAP oncogenic activity by stabilizing AMOT family proteins ([@b28-ol-0-0-9551],[@b59-ol-0-0-9551]). Tankyrases bind to AMOTs, and tankyrase-mediated PARsylation induces their degradation through E3 ligase RNF146 ([@b28-ol-0-0-9551],[@b59-ol-0-0-9551]). These observations highlight the therapeutic potential of tankyrase inhibitors in cancer, targeting the YAP oncogenic pathway. YAP signaling has been associated with drug resistance in cancer types, including lung cancer, and hence YAP signaling inhibition is important to overcome drug resistance ([@b84-ol-0-0-9551]). Tankyrase inhibition enhances EGFR inhibitor growth inhibition in lung cancer cells via AMOT stabilization and YAP signaling inhibition ([@b59-ol-0-0-9551]). Thus, tankyrase inhibition may be an effective approach to overcoming drug resistance for combinatorial cancer therapy.

### ABRO1

During the S phase, DNA must not only be replicated, but also newly synthesized DNA molecules must also be connected with each other ([@b85-ol-0-0-9551]). This sister chromatid cohesion is essential for chromosome segregation during mitosis. Canudas and Smith ([@b86-ol-0-0-9551]) demonstrated that premature resolution of telomere cohesion between sister telomeres induced sister telomere loss. Resolution at telomeres requires TNKS1, but TNKS1 mechanisms in timely resolution of sister telomere cohesion are poorly understood. Tripathi and Smith ([@b29-ol-0-0-9551]) identified ABRO1, the scaffold subunit of the BRCC36 deubiquitinating enzyme (BRISC DUB) and demonstrated that sister telomere resolution timing was ensured through cell cycle-regulated ubiquitination of TNKS1 by RNF8 ligase and the BRISC DUB. Perturbation of this regulation results in persistent unresolved cohesion in mitosis or premature loss of cohesion in the S phase, indicating that a cell cycle-regulated post-translational modification controls sister telomere cohesion timing to ensure genome integrity.

### CD2 associated protein

The adapter protein CD2AP is essential for kidney ultrafiltration and is expressed primarily by podocytes in the kidney. Podocyte damage results in numerous glomerular diseases, including nephritic syndrome and nephrotic syndrome ([@b87-ol-0-0-9551]). Kuusela *et al* ([@b30-ol-0-0-9551]) demonstrated that tankyrases interact with CD2AP, and CD2AP is a negative tankyrase regulator. Tankyrase inhibition in the absence of CD2AP increases kidney damage, which indicates that tankyrases are essential for maintaining normal kidney function ([@b87-ol-0-0-9551]).

### PEX14 and ATG9A

Li *et al* ([@b31-ol-0-0-9551]) investigated the tankyrase protein interaction network through proteomic analysis and identified \>100 high-confidence interacting proteins for tankyrases. In particular, they demonstrated that TNKS1 and TANK2 bind to the peroxisome protein PEX14 and localize on peroxisomes. Overexpression of TNKS1 or TANK2 decreases peroxisome number or size, indicating that TNKS1 and TANK2 promote pexophagy. This study also demonstrated that tankyrases associate with the autophagy-associated protein ATG9A. Additionally, they indicated that tankyrase may associate PEX14 with ATG9A to promote pexophagy. Further experimentation is required to confirm the detailed mechanism. This study provides insights into further cellular localizations and functions.

6.. Conclusions
===============

Tankyrases have been implicated in a variety of cellular functions and are important therapeutic targets; however, the details of tankyrase functions and molecular mechanisms remain unclear. Novel tankyrase binding partners, including PTEN, AMOTs, CD2AP, APC2, ABRO1, PrxII, PEX14 and ATG9A have been recently reported, and these proteins will provide novel insights to understand the functions and mechanisms of tankyrase.

A number of tankyrase substrates are tumor suppressors, including AXIN, PTEN and AMOTs. Due to tankyrase inhibitors targeting different oncogenic pathways, including WNT, AKT and YAP, tankyrases may be effective targets for cancer therapy.
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###### 

A summary of updated tankyrase-binding proteins.

  Authors, year              Novel tankyrase-binding partners   Tankyrase-binding motif   (Refs.)
  -------------------------- ---------------------------------- ------------------------- ----------------------
  Li *et al*, 2015           PTEN                               RXXXDG                    ([@b16-ol-0-0-9551])
  Kang *et al*, 2017         PrxII                              N.D.                      ([@b26-ol-0-0-9551])
  Croy *et al*, 2016         APC2                               RXXXXG                    ([@b27-ol-0-0-9551])
  Wang *et al*, 2015         AMOTs                              RXXPXG                    ([@b28-ol-0-0-9551])
  Tripathi and Smith, 2017   ABRO1                              RXXAXG                    ([@b29-ol-0-0-9551])
  Kuusela *et al*, 2016      CD2AP                              N.D.                      ([@b30-ol-0-0-9551])
  Li *et al*, 2017           PEX14                              RXXXXG, RXXXDG            ([@b31-ol-0-0-9551])
  Li *et al*, 2017           ATG9A                              RXXXXG                    ([@b31-ol-0-0-9551])

N.D., not determined; PTEN, phosphatase and tensin homolog; AMOTs, angiomotins; CD2AP, cluster of differentiation 2-associated protein; ABRO1, abraxas brother 1; APC2, adenomatous polyposis coli 2; PEX14, peroxisomal biogenesis factor 14; PrxII, peroxiredoxin II; ATG9A, autophagy related 9A.

###### 

Tankyrase inhibitors as therapeutic targets for cancer.

  Author, year                Tankyrase inhibitors   Cancer type     (Refs.)
  --------------------------- ---------------------- --------------- ----------------------
  Stratford *et al*, 2014     JW 74                  Osteosarcoma    ([@b79-ol-0-0-9551])
  Tian *et al*, 2013                                 NB              ([@b17-ol-0-0-9551])
  Huang *et al*, 2009         XAV939                 CRC             ([@b15-ol-0-0-9551])
  Busch *et al*, 2013                                Lung cancer     ([@b52-ol-0-0-9551])
  Bao *et al*, 2012                                  Breast cancer   ([@b77-ol-0-0-9551])
  Quackenbush *et al*, 2016   AZ1366                 CRC             ([@b78-ol-0-0-9551])
  Busch *et al*, 2013         IWR-1                  Lung cancer     ([@b52-ol-0-0-9551])
  Lau *et al*, 2013           G007-LK                CRC             ([@b47-ol-0-0-9551])
  Waaler *et al*, 2012        JW55                   CRC             ([@b48-ol-0-0-9551])
  Arqués *et al*, 2016        NVP-TNKS656            NSCLC           ([@b76-ol-0-0-9551])
  Wang *et al*, 2016                                                 ([@b59-ol-0-0-9551])

NB, neuroblastoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer.
